Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...
The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of ...
Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk ...
Wall Street Journal on MSN17h
Novo Nordisk Says White House Obesity Plan Is Step in Right DirectionNovo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that ...
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including ...
Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback